Location: Foreign Animal Disease Research2013 Annual Report
1a. Objectives (from AD-416):
The objective of this project is to import cells producing monoclonal antibodies specific for bovine cells produced and characterized at the International Livestock Research Institute (ILRI). This requires ILRI to determine the viability of the antibody cell lines and ARS, PIADC to test for the presence of foreign animal diseases in vivo. Once cleared, the cell lines will be made available to colleagues in Foot-and-Mouth Disease free countries and/or deposited in the American Tissue Culture Collection for general distribution. These antibodies will become available to scientists in the United States to facilitate analysis of bovine immune responses and vaccine development.
1b. Approach (from AD-416):
ARS, PIADC and the International Livestock Research Institute, Nairobi, Kenya (ILRI) will determine a list of high-priority cell lines. ILRI will test for viability and antibody production. These cell lines will be transferred to PIADC and safety tested at PIADC under BSL-3 conditions. Upon successful safety testing, the cell lines will be prepared for distribution to colleagues in North America and Europe through the use of a material transfer agreement between ILRI, ARS and recipient.
3. Progress Report:
During this reporting period, the first 30 of these lines were transferred from the Foreign Animal Disease Diagnostics Laboratory (FADDL), APHIS to ARS, PIADC following successful safety testing. All of these hybridomas were thawed and grown, and fresh aliquots refrozen for distribution. Antibodies produced by these cell lines were tested and shown to have the correct reactivity. The second 30 cell lines were imported and safety tested by FADDL, testing negative for all agents in the panel. As soon as the final report is issued and the cell lines are cleared, these will be thawed, grown, and fresh aliquots will be refrozen. Supernatants of the hybridomas will be tested and once the cell lines are shown to be producing the correct antibody, these cell lines will also become available for distribution. No publications were produced during FY 2013.